Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | MAT2A | P31153 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.30 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.30 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26675398 | 0.80 | L3MBTL1 (0.38) | P2RX7MAT2AALDH1A1GAAMAPT | |
| SCHEMBL30675628 | 0.80 | L3MBTL1 (0.38) | P2RX7MAT2AALDH1A1GAAMAPT | |
| SCHEMBL1513037 | 0.75 | ABCC8 (0.46) | ALDH1A1GAAMAPTRAB9ACLK4 | |
| SCHEMBL10884409 | 0.72 | KMT2A (0.46) | GAAMAPT | |
| SCHEMBL29110299 | 0.67 | ALDH1A1 (0.41) | ALDH1A1GAAMAPT | |
| SCHEMBL30611217 | 0.67 | ALDH1A1 (0.41) | ALDH1A1GAAMAPT | |
| SCHEMBL21145512 | 0.67 | ADORA2A (0.57) | P2RX7MAT2AALDH1A1GAA | |
| SCHEMBL30499843 | 0.67 | ALDH1A1 (0.41) | MAT2AALDH1A1GAAMAPTRAB9A | |
| SCHEMBL20354826 | 0.66 | TRPV4 (0.42) | P2RX7MAT2AALDH1A1GAAMAPT | |
| SCHEMBL2248213 | 0.66 | ALDH1A1 (0.40) | P2RX7ALDH1A1GAAMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937648-B1 | DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI SA (FR) | 2014-11-26 | — | — | EP | disclosed |
| US-8357698-B2 | Diacyl indazole derivatives as lipase and phospholipase inhibitors | SANOFI (FR) | 2013-01-22 | — | — | US | disclosed |
| US-20100286133-A1 | Diacyl indazole derivatives as lipase and phospholipase inhibitors | SANOFI-AVENTIS (FR) | 2010-11-11 | — | — | US | disclosed |
| US-7772268-B2 | inhibitors of hormone-sensitive lipase and/or endothelial lipase; for treatment of diabetes mellitus, dyslipidemia and atherosclerotic disorders | SANOFI-AVENTIS (FR) | 2010-08-10 | — | — | US | disclosed |
| US-20080287448-A1 | Diacyl indazole derivatives as lipase and phospholipase inhibitors | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| EP-1937648-A1 | DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | sanofi-aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007042178-A1 | DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287448-A1 | Diacyl indazole derivatives as lipase and phospholipase inhibitors | PNLIP, DAGLA, MGLL | P2RX7 247/4885MAT2A 3244/4885ALDH1A1 959/4885 |
| US-20100286133-A1 | Diacyl indazole derivatives as lipase and phospholipase inhibitors | PNLIP, DAGLA, MGLL | P2RX7 247/4885MAT2A 3244/4885ALDH1A1 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.